NanoViricides Inc (NNVC)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$1.29-6.52%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · NNVC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026, NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clini…
Stated in 1 of 1 supplied quarters. Management reported: “The Company expects to receive aggregate gross proceeds of ~$2 million from the Offering, before deducting placement agent fees and other related expenses.” “The Company expects to receive aggregate gross proceeds of ~$3.8 million from the Offering, before deducting placement agent fees and other related expenses.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Exhibit 99.1 NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering SHELTON, CT Friday, May 15, 2026 NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a…”
About NanoViricides NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivira…
Stated in 1 of 1 supplied quarters. Management reported: “About NanoViricides NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape.” “About NanoViricides NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape.”
“About NanoViricides NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivira…”
Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an “Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD).
Stated in 1 of 1 supplied quarters. Management reported: “Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD).” “Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an “Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD).”
“Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD).”
Continue managing operating losses and cash burn to sustain company operations.
Over the trailing year it converted 0.66x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.